CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details

Project Number PC0182-000
Brand Name Kadcyla
Generic Name Trastuzumab Emtansine
Strength 100 mg and 160 mg vial
Tumour Type Breast
Indication Early Breast Cancer (EBC)
Funding Request For the adjuvant treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progression or unacceptable toxicity. If KADCYLA is discontinued in the event of toxicity, treatment with trastuzumab may be continued to complete one year of HER2-directed therapy.
Review Status Complete
Pre Noc Submission Yes
NOC Date November 25, 2019
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date July 2, 2019
Submission Deemed Complete July 16, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ July 16, 2019
Check-point meeting August 28, 2019
pERC Meeting December 12, 2019
Initial Recommendation Issued January 3, 2020
Feedback Deadline ‡ January 17, 2020
pERC Reconsideration Meeting (target date)
Final Recommendation Issued January 22, 2020
Notification to Implement Issued February 6, 2020
Therapeutic Area Early Breast Cancer (EBC)
Recommendation Type Reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.